Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Jubilant Life Sciences — Investor Presentation (June 2020)
46 slides from Jubilant Pharmova's investor presentation, June 2020
Slide 1: Jubilant Life Sciences Limited Investor Presentation June 2020
Jubilant Life Sciences Limited Investor Presentation June 2020
Slide 2: Disclaimer
Disclaimer Important Disclaimer This presentation (the “Presentation”, or the “document”) has been prepared by Jubilant Life Sciences Limited (the “Company”) for the recipient for the purpose of providing information on the Company. The contents of this Presentation are confidential and strictly for
Slide 3: Jubilant Life Sciences Overview
Jubilant Life Sciences Overview Pharmaceuticals Life Science Ingredients DDDS1 Specialty Pharmaceuticals Specialty Intermediates Drug Discovery Radiopharma Advanced Intermediates Services (Jubilant Allergy Therapy Products Specialty Ingredients Biosys & Jubilant Chemsys) CDMO Nutritional Pro
Slide 4: Pharmaceuticals Segment
WV jusiant Pharmaceuticals Segment LIFESCIENCES
Slide 5: Evolution of Jubilant Pharma
Evolution of Jubilant Pharma Revenue Contribution JLL acquired Acquired a majority stake Acquired Draxis Pharma SGX‐listed high Completed FY20 API business – in Cadista Holdings Inc. Inc. in Canada yield bond acquisition of US$803m Nanjangud, (generics pharmaceutical (manufacturer of sterile offerin
Slide 6: Radiopharmaceuticals Business
Radiopharmaceuticals Business Market Size of Industry in North America 3.5 Radiopharmaceuticals Industry in North America is US$2.4bn, expected to grow at CAGR of 6.2% to reach 2.9 3.0 3.2 2.6 2.7 2.2 2.3 2.4 US$3.5bn by 2023 1.9 2.0 Industry (US$bn) Overview (1) Oncology and cardiology diagnosi
Slide 7: Radiopharmacy Business
Radiopharmacy Business # 2 commercial radiopharmacy network(1) in the US, operated under the Jubilant Radiopharmacy brand Facilities include three cyclotrons Multi‐year agreements with GPOs in place Over 50 radiopharmacies spread across 22 states ~750 employees c.3 mn+ doses delivered annually
Slide 8: Allergy Therapy Business
Allergy Therapy Business Allergen Immunotherapy (AIT) Market Size 2.8 Global AIT market stands at US$1.8bn and is expected to grow at CAGR of 8.9% to reach 2.3 2.6 2.1 0.5 US$2.8bn by 2022 2.0 0.4 1.7 1.8 0.4 1.6 1.6 0.3 0.3 1.4 1.4 0.3 Industry Major growth drivers include the increased prevale
Slide 9: Contract Manufacturing Business – Sterile Injectables and Non-Sterile Products
Contract Manufacturing Business – Sterile Injectables and Non‐Sterile Products Global Pharmaceutical CMO Industry Size 125 134 100 109 117 5 5 7 Injectable market stands at US$5.4bn and is expected to outpace the industry (ex API) by growing at a 5 127 12 79 85 92 4 5 11 6 6 73 6 11 4 11 Industry
Slide 10: API Business
API Business Global Market Size : Synthetic API1 149 123 131 129 Global Synthetic API market is US$115bn in 2018 and is expected to grow at a 115 Industry 46 62 51 53 (US$bn) CAGR of 6.7% from 2018 to 2022F to reach US$149bn(1) 48 Overview 53% of outsourced API market is generics(1) 67 72 78 83
Slide 11: Solid Dosage Formulations Business
Solid Dosage Formulations Business Global Generics Pharmaceuticals Industry Size by Unbranded Generic US Patent Expiry for Small Molecules Sales(1)(3) Global generics pharmaceutical industry stands at US$111bn and is expected to grow at CAGR of 5.2% to reach US$136bn US$ 72.5 bn 136 by 2023 117 12
Slide 12: Life Science Ingredients Segment
Life Science Ingredients Segment
Slide 13: Specialty Intermediates & Nutritional Products
Specialty Intermediates & Nutritional Products Global Market Size ($ Mn) : Speciality Chemicals Global Market Size (KT): Vitamin B3 Global specialty chemicals market is USD 1.1 billion in 2018 and is expected to grow at 5.4% to reach USD 1.2 Industry billion in 2022. Overview Global nutrition ma
Slide 14: Life Science Chemicals
Life Science Chemicals Global Market Size (KT): Acetic Global Market Size (KT): Ethyl Anhydride Acetate Global Acetic Anhydride market is 585 KT in 2018 and is expected to Industry grow at 4.2% to reach 662KT in 2022 Overview Global Ethyl Acetate market is 2046 KT in 2018 and is expected to grow
Slide 15: Jubilant Life Sciences – Key Strengths & Strategies
Jubilant Life Sciences – Key Strengths & Strategies
Slide 16: Jubilant Life Sciences Key Strengths
Jubilant Life Sciences Key Strengths 1 Strong Leadership in Key Products and Markets 2 Global Competitive Edge Due to Low Cost and Vertical Integration 3 De‐risked Business Model With Diverse Sources of Revenue 4 Strong Pipeline of Products with Deep R&D Capabilities 5 High‐Quality, World –Class, Lo
Slide 17: Specialty Pharmaceuticals
Leading Market Positions Across Business Lines, with High Barriers To 1 Entry For Specialty Pharmaceuticals Highlights Entry Barriers #3 radiopharmaceuticals manufacturer in the US (1) Extensive regulatory and licensing requirements #2 commercial radiopharmacy network in the US (1) Specialty P
Slide 18: Global Competitive Edge Due to Low Cost and Vertical Integration
Global Competitive Edge Due to Low Cost and Vertical 2 Integration Vertical integration across the value chain enables cost competitive advantage resulting in higher margins Integrated Operations… Life Sciences Ingredients Radiopharmacies Provides direct access to hospital networks ‐ ability to de
Slide 19: De-risked Business Model With Diverse Sources of Revenue
3 De‐risked Business Model With Diverse Sources of Revenue Presence in niche Specialty businesses that have high barriers to entry Diverse end‐use industry segmentation in Life Science Ingredients with focus on Pharmaceutical and Agrochemical industries Presence across geographic locations ena
Slide 20: Strong Pipeline of Products With Deep R&D Capabilities
4 Strong Pipeline of Products With Deep R&D Capabilities Strong R&D capabilities demonstrated by complex and niche product filings including 505(b)(2) in radiopharma Strong R&D support with a dedicated workforce of ~500 R&D professionals. 919 patents filed till FY20 Strong pipeline of 8 produc
Slide 21: High-Quality, World-Class, Low Cost Manufacturing Footprint
5 High‐Quality, World‐Class, Low Cost Manufacturing Footprint Spokane, Washington, USA Roorkee, Uttarakhand Contract manufacturing of Sterile Generics manufacturing injectable and Allergy therapy Gajraula, Uttar Pradesh Largest integrated facility of Specialty Intermediates and Samlaya, Gujara
Slide 22: Experienced Management Team with High Standards of Corporate Governance
Experienced Management team with high standards of corporate 6 governance Shyam S Bhartia Hari S Bhartia Chairman Co‐Chairman & Managing Director 39 industry years in pharma, specialty 33 industry years in pharma, specialty chemicals, foods, oil and gas, aerospace and IT chemicals, foods, oil and ga
Slide 23: Demonstrated Financial Track Record with Strong Revenue Growth
Demonstrated Financial Track Record with Strong Revenue Growth and 7 Attractive Profitability Profile Revenue from Operations1 Total Revenue EBITDA Split1 Reported EBITDA2 Revenue increased at a CAGR of 9.5% over FY15‐20 and EBITDA 5,826 5,893 5,861 7,518 9,111 9,154 732 1,291 1,370 1,558 1,775 1,
Slide 24: Growth Strategies and Plans
Growth Strategies and Plans Continue to strengthen leadership positions in key business segments 1 Radiopharma: Achieve market leadership by leveraging leadership in existing products and broad distribution network along with expansion of our product portfolio through launch of niche and different
Slide 25: Growth Strategies and Plans
Growth Strategies and Plans 3 Develop a diverse product and service portfolio through differentiated and complex offerings Specialty Pharmaceuticals Focus: Develop differentiated products in the radiopharmaceuticals and specialty injectables segments catering to the North American market CDMO Fo
Slide 26: Q4 & 12M'FY20 Results Analysis
Q4 & 12M’FY20 Results Analysis
Slide 27: Chairmen's Message
Chairmen’s Message JUBILANT Q4’FY20 & FY20 PERFORMANCE FY20 Revenue at Rs 9,154 Crore; Q4’FY20 Revenue at Rs 2,391 Crore FY20 EBITDA at Rs 1,995 Crore up 12% YoY; Q4’FY20 EBITDA at Rs 556 Crore up 58% YoY Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co‐C
Slide 28: Update on Reorganization Proposal
Update on Reorganization Proposal Post the board approval on Oct 25, 2019 for reorganizing the businesses of the Company, in November 2019, the Company had filed with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) the Composite Scheme of Arrangement for amalgamation of certai
Slide 29: Q4'FY20 Results Analysis
Q4’FY20 Results Analysis Ww J' UBILANT ‘LIFESCIENCES
Slide 30: JLL – Q4'FY20 Financial Highlights
JLL – Q4’FY20 Financial Highlights Revenue at Rs 2,391 Crore, as compared with Rs 2,386 Crore in Q4’FY19 • Pharmaceuticals revenue at Rs 1,483 Crore, an increase of 6% YoY, contributing 62% to revenue • LSI revenue at Rs 823 Crore decreased by 10% YoY and increased by 3% QoQ • Drug Discovery & Dev
Slide 31: Pharmaceuticals Segment Highlights – Q4'FY20 (1/2)
Pharmaceuticals Segment Highlights – Q4’FY20 (1/2) Particulars1 Q4'FY19 Q4'FY20 % Change Pharmaceuticals revenue at Rs 1,483 Crore, an increase of 6% YoY and Revenue 1,405 1,483 6% 2% QoQ. Specialty Pharma and Generics segments increased by 13% YoY Specialty Pharma 695 787 13% and 17% YoY, respect
Slide 32: Pharmaceuticals Segment Highlights – Q4'FY20 (2/2)
Pharmaceuticals Segment Highlights – Q4’FY20 (2/2) USFDA Inspection Details Generics1 (21% of Pharma Revenues) • Revenue was up 17% YoY and 5% QoQ due to better performance in the Facility Last Inspection US market, which witnessed higher volumes and better prices Montreal, CMO May, 2018 • Establish
Slide 33: LSI Segment Highlights – Q4'FY20
LSI Segment Highlights – Q4’FY20 Particulars1 Q4'FY19 Q4'FY20 % Change LSI revenue at Rs 823 Crore, decreased by 10% YoY and increased by 3% Revenue 912 823 (10%) QoQ. Though Strong growth witnessed in Nutritional Products however Specialty Intermediates 328 286 (13%) Specialty Intermediates busin
Slide 34: Drug Discovery & Development Solutions – Q4'FY20
Drug Discovery & Development Solutions – Q4’FY20 Particulars1 Q4'FY19 Q4'FY20 % Change Drug Discovery & Development Solutions (DDDS) comprises Revenue 68 85 25% Drug Discovery Services 68 85 25% • Drug Discovery Services business through Jubilant Biosys Proprietary Drug Discovery 0 0 ‐ Limited & J
Slide 35: Proprietary Drug Discovery (Jubilant Therapeutics)
Proprietary Drug Discovery (Jubilant Therapeutics) Jubilant Therapeutics is a patient‐focused biopharmaceutical company working to address unmet medical needs in oncology and autoimmune diseases. Our advanced discovery engine integrates structure‐based design and computational architecture to disc
Slide 36: FY20 Results Analysis
FY20 Results Analysis Ww J' UBILANT ‘LIFESCIENCES
Slide 37: JLL – FY20 Financial Highlights
JLL – FY20 Financial Highlights Revenue at Rs 9,154 Crore up from Rs 9,111 Crore in FY19 • Pharmaceuticals revenue at Rs 5,714 Crore, increased by 7% YoY, contributing 62% to revenue • LSI revenue at Rs 3,179 Crore decreased 10% YoY, contributing 35% to revenue • Drug Discovery & Development Solut
Slide 38: Pharmaceuticals Segment Highlights – FY20
Pharmaceuticals Segment Highlights – FY20 Particulars1 FY19 FY20 % Change Geography Wise Revenue1 Revenue 5,349 5,714 7% Specialty Pharma 2,830 3,019 7% 4,289 4,730 Radiopharma 2,467 2,608 6% Allergy Therapy Products 362 411 14% CDMO 1,470 1,536 5% 148 137 541 473 371 375 CMO 785 896 14% API 685 640
Slide 39: Adjusted Earnings
Adjusted Earnings Rs Crore Consol EBITDA % Change % Change S. No. Particulars Q4'FY19 Q4'FY20 YoY FY19 FY20 YoY 1 Reported EBITDA 351 556 58% 1,775 1,995 12% 2 One‐off Adjustments 37 12 85 72 3 Adjusted EBITDA 388 568 46% 1,860 2,066 11% 4 Reported EBITDA Margin 14.7% 23.3% 19.5% 21.8% 5 Adjusted EB
Slide 40: LSI Segment Highlights – FY20
LSI Segment Highlights – FY20 Particulars1 FY19 FY20 % Change LSI revenue at Rs 3,179 Crore decreased by 10% YoY. Strong Revenue 3,545 3,179 (10%) growth witnessed in Specialty Intermediates and Nutritional Specialty Intermediates 1,011 1,117 10% Nutritional Products 410 537 31% Products amid lowe
Slide 41: Drug Discovery & Development Solutions – FY20
Drug Discovery & Development Solutions – FY20 Particulars1 FY19 FY20 % Change DDDS segment revenue increased 21% YoY to Rs 262 Revenue 217 262 21% Crore led by growth in Drug Discovery Services Drug Discovery Services 217 262 21% business, which was driven by higher demand from Proprietary Drug Di
Slide 42: Debt Profile
Debt Profile Particulars 31/03/19 30/12/19 31/03/20 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Subsidiaries 500 400 431 Total 500 400 431 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 1,341 1,156 1,295 Subsidiaries 61 37 100 Total 1,402 1,193 1,395 Gross Debt (Rs. Crs) (Rs. Crs) (Rs. Crs) St
Slide 43: Jubilant Life Science – Strategic Priorities
Jubilant Life Science – Strategic Priorities The Company’s strategic focus is to further strengthen its leadership position in all its businesses while creating value for its shareholders Despite the Covid‐19 impacts all around, we have taken several steps to ensure uninterrupted supplies to our
Slide 44: Appendix
Appendix 4 J' UBILANT LIFESCIENCES
Slide 45: Income Statement – Q4 & 12M'FY20
Income Statement – Q4 & 12M’FY20 Particulars1 Q4'FY19 Q4'FY20 YoY Growth FY19 FY20 YoY Growth Total Revenue from Operations 2,386 2,391 0% 9111 9,154 0% Pharmaceuticals 1,405 1,483 6% 5349 5,714 7% Life Science Ingredients 912 823 (10%) 3545 3,179 (10%) Drug Discovery & Development Solutions 68 85 2
Slide 46: For more information
For more information For Investors: Vineet Mayer Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1021 Ph: +91 22 6645 1209 E‐mail: Vineet.mayer@jubl.com E‐mail: siddharth@cdr‐india.com For Media: Sudhakar Safaya Desiree Crasto Jubilant Life Sciences Limited Madison Publi
Jubilant Life Sciences — Investor Presentation (June 2020) on 6ix